Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.

Abstract

Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.

• Authors: James F Donohue, Tara Rheault, Margot MacDonald-Berko, Thomas Bengtsson, Kathleen Rickard
• Journal: International journal of chronic obstructive pulmonary disease (Int J Chron Obstruct Pulmon Dis) Vol. 18 Pg. 1611-1622 ( 2023) ISSN: 1178-2005 [Electronic] New Zealand
• PMID: 37533771 (Publication Type: Journal Article, Review)
• Copyright: © 2023 Donohue et al.

Chemical References

• ensifentrine
• Phosphodiesterase 4 Inhibitors
• Isoquinolines
• Bronchodilator Agents

Topics

• Humans
• Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy, chemically induced)
• Quality of Life
• Phosphodiesterase 4 Inhibitors
• Isoquinolines (pharmacology)
• Administration, Inhalation
• Bronchodilator Agents